Short answer: Zinc-L-carnosine is not zinc plus carnosine — it is a single 1:1 chelate (known in Japan as polaprezinc) that dissociates slowly and adheres to damaged patches of the stomach and intestinal lining, delivering both halves of the molecule exactly where repair is happening. It has been a prescription mucosal protectant in Japan since 1994, and it carries the kind of evidence prescribers can read: a randomised crossover study in Gut in which it prevented the tripling of intestinal permeability caused by an NSAID, a 303-patient randomised trial in which adding it to standard H. pylori triple therapy lifted eradication from 58.6% to 77.0%, and a 2022 meta-analysis pooling three RCTs in its favour. It is not registered or stocked in Malaysian retail pharmacies. Lynnity prepares zinc-L-carnosine as a precision capsule or a flavoured oral liquid, on a doctor’s prescription only, under Good Compounding Practice (GCP).
Why the chelate is the story
Practitioners in KL and Singapore know zinc cold — off-the-shelf zinc salts like gluconate or citrate dissolve promptly in the stomach, get absorbed high in the gut, and behave like a systemic mineral. Zinc-L-carnosine behaves differently because of its structure: the zinc is held inside a polymeric chelate with the dipeptide L-carnosine, so it does not fall apart on contact with gastric acid. Instead it dissociates slowly, and the intact complex shows a documented affinity for ulcerated and inflamed mucosa — it physically adheres to the wound bed, something a dissolved zinc salt cannot do.
That adhesion is the pharmacological point. At the site of injury the complex releases zinc (a cofactor for the enzymes of epithelial repair and tight-junction assembly) and L-carnosine (an antioxidant dipeptide) together, over time, in the exact place they are needed. Researchers describe it as a topical action from an oral dose. Laboratory work supports the mechanism: in cell and tissue models, zinc-L-carnosine stimulated cell migration and proliferation — the two engines of mucosal restitution — and in the same research programme reduced gastric injury by around 75% and villus shortening by around 50% in pre-clinical models.
The clinical record a prescriber can check
Gut-barrier protection under NSAID stress
In a randomised, double-blind, placebo-controlled crossover study in healthy volunteers published in Gut (Mahmood et al., 2007), five days of indomethacin 50 mg three times daily tripled small-intestinal permeability on placebo — the lactulose:rhamnose ratio rose from 0.35 to 0.88 (p < 0.01). When zinc-L-carnosine 37.5 mg twice daily was co-administered, no significant rise in permeability occurred. For clinics managing patients on long-term NSAIDs or aspirin, that is a measurable, mechanistic endpoint — not marketing language.
As an adjunct in H. pylori regimens
A randomised, multicentre, prospective trial in 332 patients (Tan et al., PLOS ONE, 2017) added polaprezinc 75 mg twice daily to standard omeprazole–amoxicillin–clarithromycin triple therapy. Eradication rose from 58.6% to 77.0% on intention-to-treat analysis, and from 61.4% to 81.1% per-protocol (both p < 0.01), with no increase in adverse events at the standard dose. A 2022 systematic review and meta-analysis pooling three RCTs (n = 396) reached the same direction of effect — odds ratio 2.01 for eradication on intention-to-treat, 2.65 per-protocol. The context matters in our region: clarithromycin resistance is a growing problem across Asia, and these trials suggest a non-antibiotic adjunct can claw back some of the lost eradication rate. The regimen itself — antibiotics, acid suppression, retesting — remains entirely the treating doctor’s territory.
The wider Japanese literature
Three decades of prescription use in Japan have also produced supporting studies in radiotherapy-associated oral mucositis, taste disturbance and aspirin-related small-bowel injury — smaller, largely Japanese-population work we cite as context, not proof.
Why it reaches a compounding pharmacy in Malaysia
Polaprezinc is registered as a medicine in Japan and a handful of Asian markets — but not in Malaysia, and you will not find the chelate on a Klang Valley retail shelf next to the zinc gluconate. When a prescriber wants the studied molecule at the studied dose, that becomes a compounding request. At Lynnity, under Good Compounding Practice (GCP), we can prepare:
A precision capsule at the trial-anchored strengths — commonly 37.5 mg or 75 mg twice daily as directed by the prescriber — using an excipient-minimal fill for sensitive gastrointestinal patients. A flavoured oral liquid for patients who cannot swallow capsules; because zinc-L-carnosine acts luminally, a liquid that coats on the way down is a pharmacologically sensible format, and palatability can be tuned for adults or, on paediatric prescription, for children. A combination capsule where the doctor wants it alongside partners from a gut-repair protocol — for example with tributyrin or lactoferrin — combined into one capsule to protect adherence. Every preparation carries a beyond-use date assigned under GCP.
Where does it fit clinically? That is the prescriber’s call, but the referral patterns we see from KL and Singapore clinics cluster around patients on long-term NSAIDs or aspirin, adjunctive support around doctor-managed H. pylori treatment, and gut-barrier support in functional-medicine protocols — including patients whose GLP-1 therapy is causing gastrointestinal grumbling their doctor wants to soften.
For clinics and practitioners
Lynnity is a prescription-only compounding pharmacy in Kuala Lumpur serving doctors, dietitians, nutritionists, pharmacists and wellness clinics across the Klang Valley and Singapore. Every preparation — supplements included — requires a prescription from a registered doctor. If zinc-L-carnosine belongs in one of your protocols, send the prescription with the intended strength and format, and our pharmacists will confirm formulation, stability and beyond-use dating with you before we compound.
Frequently asked questions
Is zinc-L-carnosine the same as taking zinc and carnosine together?
No. Mixing a zinc salt with L-carnosine gives you two dissolved ingredients absorbed high in the gut. The chelate is a single molecule that resists gastric acid, adheres to damaged mucosa and dissociates slowly at the site — the adhesion is the mechanism, and it only exists in the chelated form.
What did the trials actually show?
Two headline results: co-administration prevented the NSAID-induced tripling of intestinal permeability in a small crossover RCT (Gut, 2007), and adding it to H. pylori triple therapy improved eradication from 58.6% to 77.0% ITT in a 332-patient randomised trial (PLOS ONE, 2017), a finding supported by a 2022 meta-analysis. Studies are encouraging but modest in size — we present them as evidence for a prescriber to weigh, not as promises.
Can it replace antibiotics or my gastric medication?
No. In every positive trial it was an adjunct to standard doctor-prescribed treatment, never a replacement. Decisions about eradication regimens, acid suppression and follow-up testing belong to your treating doctor.
If it’s a medicine in Japan, why compound it in Malaysia?
Because it is not registered in Malaysia, so there is no local product a prescriber can dispense. Compounding under GCP is the legitimate route for a doctor to prescribe the studied molecule at the studied dose for an individual patient.
Can I buy compounded zinc-L-carnosine from Lynnity directly?
No. Every Lynnity preparation — supplements included — requires a prescription from a registered doctor in Malaysia. Your doctor or clinic can refer you, and Lynnity works with the prescriber on the exact formulation.
Who should be cautious with it?
Pregnant and breastfeeding women and children, unless a doctor specifically prescribes it; anyone using long-term zinc, because sustained zinc can deplete copper; and anyone with gastric symptoms who has not been properly investigated — mucosal support is never a reason to delay endoscopy or eradication testing your doctor recommends.
Reviewed by the Lynnity pharmacist team · Lynnity Compounding Pharmacy, Kuala Lumpur · Prescription-only · Good Compounding Practice (GCP)